Get started
Author

Seung Hyun Jung

ORCID: 0009-0003-7391-8779
Observed ORCID: 0009-0003-7391-8779
OpenAlex ID: A5038848372
Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2024 · Himangshu Sonowal, William G. Rice, et al. · Cancer Research Communications · 9
PDF
Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Abstract 1770: HM100760, a potent and selective MAT2A inhibitor, demonstrates a synergistic anticancer effect when combined with a PRMT5 inhibitor in MTAP-deleted cancer
2025 · Minjeong Kim, Eun Joo Kwak, et al. · Cancer Research
Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025 · Himangshu Sonowal, William G. Rice, et al.
Works count: 39
Citation count: 9
H-index: 1
I10-index:
Year
Topic
Type